FDU Clinic
Randomized Controlled Study Comparing Drug LABI123 vs Crizalizumab in the Treatment of Vaso-Occlusive Pain Crisis
If you have any questions, you can ask us by clicking the icon Speech Balloon in the lower right corner
About Study NCTFDU98765432
Randomized, Open-label, Multicentered, Prospective, Phase III Trial to Assess the Efficacy and Safety of LABI123 vs. Crizanlizumab in Patients Experiencing Vaso-Occlusive Pain
Who We Are
Scientists work every day to provide the best treatment regimens for Vaso-Occlusive Pain Crisis
  • Ihor Filipp
  • Anna Stark
    Head of recruiter department
  • Julia Bush
    Director of Q&A
  • Carlos Lott